Radiomics models to predict bone marrow metastasis of neuroblastoma using CT

Cancer Innovation Pub Date : 2024-06-28 DOI:10.1002/cai2.135
Xiong Chen, Qinchang Chen, Yuanfang Liu, Ya Qiu, Lin Lv, Zhengtao Zhang, Xuntao Yin, Fangpeng Shu
{"title":"Radiomics models to predict bone marrow metastasis of neuroblastoma using CT","authors":"Xiong Chen,&nbsp;Qinchang Chen,&nbsp;Yuanfang Liu,&nbsp;Ya Qiu,&nbsp;Lin Lv,&nbsp;Zhengtao Zhang,&nbsp;Xuntao Yin,&nbsp;Fangpeng Shu","doi":"10.1002/cai2.135","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Bone marrow is the leading site for metastasis from neuroblastoma and affects the prognosis of patients with neuroblastoma. However, the accurate diagnosis of bone marrow metastasis is limited by the high spatial and temporal heterogeneity of neuroblastoma. Radiomics analysis has been applied in various cancers to build accurate diagnostic models but has not yet been applied to bone marrow metastasis of neuroblastoma.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We retrospectively collected information from 187 patients pathologically diagnosed with neuroblastoma and divided them into training and validation sets in a ratio of 7:3. A total of 2632 radiomics features were retrieved from venous and arterial phases of contrast-enhanced computed tomography (CT), and nine machine learning approaches were used to build radiomics models, including multilayer perceptron (MLP), extreme gradient boosting, and random forest. We also constructed radiomics-clinical models that combined radiomics features with clinical predictors such as age, gender, ascites, and lymph gland metastasis. The performance of the models was evaluated with receiver operating characteristics (ROC) curves, calibration curves, and risk decile plots.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The MLP radiomics model yielded an area under the ROC curve (AUC) of 0.97 (95% confidence interval [CI]: 0.95–0.99) on the training set and 0.90 (95% CI: 0.82–0.95) on the validation set. The radiomics-clinical model using an MLP yielded an AUC of 0.93 (95% CI: 0.89–0.96) on the training set and 0.91 (95% CI: 0.85–0.97) on the validation set.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>MLP-based radiomics and radiomics-clinical models can precisely predict bone marrow metastasis in patients with neuroblastoma.</p>\n </section>\n </div>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212276/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Innovation","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cai2.135","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Bone marrow is the leading site for metastasis from neuroblastoma and affects the prognosis of patients with neuroblastoma. However, the accurate diagnosis of bone marrow metastasis is limited by the high spatial and temporal heterogeneity of neuroblastoma. Radiomics analysis has been applied in various cancers to build accurate diagnostic models but has not yet been applied to bone marrow metastasis of neuroblastoma.

Methods

We retrospectively collected information from 187 patients pathologically diagnosed with neuroblastoma and divided them into training and validation sets in a ratio of 7:3. A total of 2632 radiomics features were retrieved from venous and arterial phases of contrast-enhanced computed tomography (CT), and nine machine learning approaches were used to build radiomics models, including multilayer perceptron (MLP), extreme gradient boosting, and random forest. We also constructed radiomics-clinical models that combined radiomics features with clinical predictors such as age, gender, ascites, and lymph gland metastasis. The performance of the models was evaluated with receiver operating characteristics (ROC) curves, calibration curves, and risk decile plots.

Results

The MLP radiomics model yielded an area under the ROC curve (AUC) of 0.97 (95% confidence interval [CI]: 0.95–0.99) on the training set and 0.90 (95% CI: 0.82–0.95) on the validation set. The radiomics-clinical model using an MLP yielded an AUC of 0.93 (95% CI: 0.89–0.96) on the training set and 0.91 (95% CI: 0.85–0.97) on the validation set.

Conclusions

MLP-based radiomics and radiomics-clinical models can precisely predict bone marrow metastasis in patients with neuroblastoma.

Abstract Image

利用CT预测神经母细胞瘤骨髓转移的放射组学模型
背景:骨髓是神经母细胞瘤转移的主要部位,影响神经母细胞瘤患者的预后。然而,由于神经母细胞瘤在空间和时间上的高度异质性,骨髓转移的准确诊断受到了限制。放射组学分析已应用于多种癌症,以建立准确的诊断模型,但尚未应用于神经母细胞瘤的骨髓转移:我们回顾性地收集了 187 例经病理诊断为神经母细胞瘤患者的信息,并按 7:3 的比例将其分为训练集和验证集。我们从造影剂增强计算机断层扫描(CT)的静脉期和动脉期提取了共 2632 个放射组学特征,并使用九种机器学习方法建立放射组学模型,包括多层感知器(MLP)、极梯度提升和随机森林。我们还构建了放射组学-临床模型,将放射组学特征与年龄、性别、腹水和淋巴腺转移等临床预测因素相结合。我们用接收者操作特征曲线(ROC)、校准曲线和风险十等分图来评估模型的性能:MLP 放射组学模型在训练集上的 ROC 曲线下面积(AUC)为 0.97(95% 置信区间 [CI]:0.95-0.99),在验证集上的 ROC 曲线下面积(AUC)为 0.90(95% 置信区间 [CI]:0.82-0.95)。使用 MLP 的放射组学-临床模型在训练集上的 AUC 为 0.93(95% CI:0.89-0.96),在验证集上的 AUC 为 0.91(95% CI:0.85-0.97):基于MLP的放射组学和放射组学-临床模型可以准确预测神经母细胞瘤患者的骨髓转移。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.70
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信